AstraZeneca was forced to withdraw from two clinical trials of the drug for the treatment of Alzheimer’s disease – the medicines company once hoped to reach $5 billion (£3.8 billion) in annual sales.
The FTSE 100 giant said an independent panel judged lanabecestat drug that was tested on patients – will not meet its clinical objectives in both processes.
In the news as astrazeneca and its joint venture partner, us drugs firm Eli Lilly. The Duo entered into a joint venture $500 million to develop the drug four years ago.
At that time, AstraZeneca chief Executive Pascal Soriot said he looked forward to medicine eventually, will reach $5 billion in sales.
Lanabecestat belongs to a class of drugs known as inhibitors Vasya’,…
Sign up for free to read this article, or log in to your account the Telegraph